BOSTON, April 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on May 4, 2016, to discuss financial results of the first quarter ended March 31, 2016. The call details are as follows:
The teleconference replay will be available at approximately one hour after completion through Thursday, May 12, 2016, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10083822.
The archived webcast will be available for one year via the aforementioned URLs.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies. Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 / firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-first-quarter-2016-results-on-may-4-2016-300257481.html
SOURCE Juniper Pharmaceuticals, Inc.